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Abstract: A series of nineteen N-(alkoxyphenyl)-2-hydroxynaphthalene-1-carboxamides and a
series of their nineteen positional isomers N-(alkoxyphenyl)-1-hydroxynaphthalene-2-carboxamides
were prepared and characterized. Primary in vitro screening of all the synthesized compounds
was performed against Mycobacterium tuberculosis H37Ra, M. kansasii and M. smegmatis. Screening
of the cytotoxicity of the compounds was performed using human monocytic leukemia THP-1
cells. Some of the tested compounds showed antimycobacterial activity comparable with or higher
than that of rifampicin. For example, 2-hydroxy-N-(4-propoxyphenyl)-naphthalene-1-carboxamide
showed the highest activity (MIC = 12 µM) against M. tuberculosis with insignificant cytotoxicity.
N-[3-(But-2-yloxy)phenyl]- and N-[4-(but-2-yloxy)phenyl]-2-hydroxy-naphthalene-1-carboxamide
demonstrated high activity against all tested mycobacterial strains and insignificant cytotoxicity.
N-(Alkoxyphenyl)-1-hydroxynaphthalene-2-carboxamides demonstrated rather high effect against
M. smegmatis and M. kansasii and strong antiproliferative effect against the human THP-1 cell line.
Lipophilicity was found as the main physicochemical parameter influencing the activity. A significant
decrease of mycobacterial cell metabolism (viability of M. tuberculosis H37Ra) was observed
using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide) assay. Structure-activity
relationships are discussed.
Keywords: hydroxynaphthalenecarboxamides; in vitro antimycobacterial activity; MTT assay;
lipophilicity; structure-activity relationships
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1. Introduction
In spite of the approval of some new antituberculosis drugs, such as bedaquillin or delamanid [1],
tuberculosis (TB) now ranks alongside human immunodeficiency virus as a leading cause of deaths
worldwide [2]. Despite the decrease in TB incidence since the 1950s due to the introduction of
new antitubercular agents to clinical practice, morbidity and mortality have risen again since the
1980s; TB has again become a major bacterial cause of worldwide mortality, and thus it remains a
serious global problem. Based on the new World Health Organization tuberculosis report, TB killed
1.5 million people in 2014 worldwide; 9.6 million people are estimated to have fallen ill with TB in
2014. As estimated, 480,000 cases of multidrug-resistant TB (MDR-TB) occurred in 2014 [2]. The rate of
successful treatments has also decreased due to the emergence of drug resistant, cross-, multidrug-,
extensively- and totally-resistant strains. The increase in the number of new infections is also associated
with immunocompromised populations. In addition, more frequent occurrences of lethal complications
associated with immunocompromised populations include systemic infections caused by common,
initially non-pathogenic mycobacterial strains (e.g., M. kansasii, M. avium, M. smegmatis, etc.), which
cause difficult-to-treat or incurable diseases due to suppressed immunity. These non-tuberculous
mycobacteria (NTM) are now recognized as significant human pathogens and cause diseases (such as
pulmonary disease, lymphadenitis, skin and soft tissue disease, gastrointestinal and skeletal infections)
that result in significant morbidity. The emergence of MDR-TB and NTM makes the discovery of new
molecular scaffolds a priority to achieve effective control of both TB and NTM [3].
Hydroxynaphthalene-2-carboxanilides can be considered as cyclic analogues of salicylanilides that
have expressed promising results as potential antimicrobial and antimycobacterial agents [4–6] (and
refs. therein)]. Their antimicrobial effects are connected with the ability of vicinal hydroxyarylamides
to inhibit various enzymatic systems in bacteria [[4–6] (and refs. therein)]. In addition, the presence of
an amide group with a hydrophobic residue in its close vicinity is able, due to its electron properties, to
interact and bind with a number of enzymes/receptors and affect the biological response by means of
these target sites. The properties of the amide moiety can be easily modified by various substitutions [7].
Thus the presence of an amide-like moiety is characteristic for various antibacterial, antimycobacterial
or antiparasitic agents [4–15].
N-Aryl-2-hydroxynaphthalene-1-carboxamides and N-aryl-1-hydroxynaphthalene-2-carbox-amides
have shown activity against mycobacterial species [11,16]; therefore various alkoxy derivatives have
been designed from 2-hydroxynaphthalene-1-carboxylic acid and 1-hydroxynaphthalene-2-carboxylic
acid. The present work is focused on synthesis and investigation of the biological activity of
ring-substituted carboxamides of the above-mentioned acids as promising antimycobacterial agents.
2. Results and Discussion
2.1. Chemistry and Physicochemical Properties
The condensation of 2-hyroxynaphthalene-1-carboxylic acid or 1-hydroxynaphthalene-2-carboxylic
acid with appropriate alkoxy-substituted anilines using phosphorus trichloride in dry chlorobenzene
under microwave conditions yielded a series of nineteen N-substituted-2-hydroxy-naphthalene-1-
carboxamides 1–7c (series I) and nineteen N-substituted-1-hydroxynaphthalene-2-carboxamides
8–14c (series II), see Scheme 1. Alkoxy-substituted anilines (except commercially available o-, m-
and p-anisidine) were prepared from corresponding aminophenol and alkyl bromide according to
De Marco et al. [17] and were reported recently [18]. Compounds 1–2c [16] and 8–9c [11] have been
already published by our team, nevertheless they are also mentioned here to complete the overview of
biological activities and structure-activity relationships.
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The ortho-substituted derivatives showed the highest calculated log P values, while para-substituted 
derivatives demonstrated the lowest log P values, except 11c (R = 4-OC3H7) and 12c (R = 4-OC4H9) that 
have the same calculated lipophilicity values as the ortho-substituted derivatives. In addition to 
lipophilicity, molar volume (MV) of substituents and electronic σ parameters of substituents are largely 
employed in structure-activity relationship analysis. The corresponding MV and σ values of phenyl 
ring substituents 1–14c are shown in Table 1 and were also predicted by ACD/Percepta. 
 
Scheme 1. Synthesis of N-(alkoxyphenyl)-2-hydroxynaphthalene-1-carboxamides 1–7c and  
N-(alkoxyphenyl)-1-hydroxynaphthalene-2-carboxamides 8–14c. Reagents and conditions: (a) PCl3, 
chlorobenzene, microwave irradiation (MW). 
Table 1. Structures of discussed ring-substituted hydroxynaphthalenecarboxamides 1–14c; calculated 
values of log P, molar volume (MV (cm3)) of R substituents and electronic σ parameters of R substituents; 
in vitro antimycobacterial activity (MIC) of compounds in comparison with isoniazid (INH) and 
rifampicin (RIF) standards; in vitro antiproliferative assay (IC50) of chosen compounds. 
Compound R log P a MV a σ a MIC (µM) IC50 (µM) 
MT MS MK 
1 H 4.49 0 0 94 486 15 >30 
2a 2-OCH3 4.54 37.15 −0.28 852 873 873 - 
2b 3-OCH3 4.51 37.15 0.11 852 218 109 - 
2c 4-OCH3 4.30 37.15 −0.27 852 436 218 - 
3a 2-OC2H5 4.88 53.66 −0.29 26 832 832 >30 
3b 3-OC2H5 4.83 53.66 0.10 813 416 208 - 
3c 4-OC2H5 4.76 53.66 −0.29 26 832 104 >30 
4a 2-OC3H7 5.22 70.16 −0.29 37 796 99 >30 
4b 3-OC3H7 5.14 70.16 0.14 46 398 199 8.97 ± 0.34 
4c 4-OC3H7 5.21 70.16 −0.28 12 398 99 >30 
5a 2-OC4H9 5.53 86.67 −0.28 745 763 763 >30 
5b 3-OC4H9 5.49 86.67 0.14 23 381 190 >30 
5c 4-OC4H9 5.54 86.67 −0.28 745 763 95 >30 
6a 2-OCH(CH3)2 5.15 70.54 −0.47 31 796 99 >30 
6b 3-OCH(CH3)2 5.06 70.54 0.10 778 398 199 8.84 ± 0.22 
6c 4-OCH(CH3)2 5.04 70.54 −0.45 25 796 99 >30 
7a 2-OCH(CH3)CH2CH3 5.47 87.05 −0.27 44 763 95 8.35 ± 1.25 
7b 3-OCH(CH3)CH2CH3 5.40 87.05 0.14 23 12 47 >30 
7c 4-OCH(CH3)CH2CH3 5.40 87.05 −0.27 23 12 95 >30 
Scheme 1. Synthesis of N-(alkoxyphenyl)-2-hydroxynaphthalene-1-carboxamides 1–7c and
N-(alkoxyphenyl)-1-hydroxynaphthalene-2-carboxamides 8–14c. Reagents and conditions: (a) PCl3,
chlorobenzene, microwave irradiation (MW).
Within structure-activity relationships, various parameters describing physicochemical properties
are investigated. Lipophilicity is a property that h s a m jor effe t n s lubility, absorption, distribution
and biotransformation as well as pharmacological activity, because drugs cross biological membranes
through passive transport, which strongly depends on their lipophilicity. Lipophilicity was observed
as the most important descriptor affecting the antimycobacterial activity for both series, see below.
In the current investigation, the lipophilicity values expressed as log P were calculated using
ACD/Percepta ver. 2012. Log P values of both series as well as the used standards isoniazid (INH)
and rifampicin (RIF) can be compared in Table 1. In general, N-(alkoxyphenyl)-1-hydroxynaphthalene-
2-carboxamides 8–14c (series II) are characterized by slightly higher calculated lipophilicity than
N-(alkoxyphenyl)-2-hydroxynaphthalene-1-carbox-amides 1–7c (series I) with the exception of
compound 3c (R = 4-OC2H5) that has higher log P value than compound 10c. Within individual series,
the lipophilicity increases as follows: OCH3 < OC2H5 < OCH(CH3)2 < OC3H7 < OCH(CH3)CH2CH3
< OC4H9. The ortho-substituted derivatives showed the highest calculated log P values, while
para-substituted derivatives demonstrated the lowest log P values, except 11c (R = 4-OC3H7) and 12c
(R = 4-OC4H9) that have the same calculated lipophilicity values as the ortho-substituted derivatives.
In addition to lipophilicity, molar volume (MV) of substituents and electronic σ parameters of
substituents are largely employed in structure-activity relationship analysis. The corresponding
MV and σ values of phenyl ring substituents 1–14c are shown in Table 1 and were also predicted
by ACD/Percepta.
2.2. In Vitro Antimycobacterial Evaluation
The evaluation of the in vitro antimycobacterial activity of the compounds was performed against
Mycobacterium tuberculosis H37Ra ATCC 25177 (MT), M. kansasii DSM 44162 (MK) and M. smegmatis
ATCC 700084 (MS), see Table 1. To lower risk and make manipulation in the laboratory easier, surrogate
model pathogens for M. tuberculosis can be used in laboratory studies. Avirulent M. tuberculosis strain
H37Ra is very closely related to and has similar pathology as human-infecting M. tuberculosis strains,
making it a good model for study especially because of the lower risk for laboratory workers [19].
M. kansasii, the most virulent of the NTM, causes nontuberculous mycobacterial lung infections,
which are now very common, and can be indistinguishable from tuberculosis [20]. M. smegmatis
is an ideal representative of a fast-growing nonpathogenic microorganism, particularly useful in
studying basic cellular processes of special relevance to pathogenic mycobacteria [21]. Therefore
additionally M. kansasii and M. smegmatis were chosen as model species for screening of prospective
antimycobacterial drugs to control mycobacterial diseases. The potency of the compounds was
expressed as the minimum inhibitory concentration (MIC) that is defined for mycobacteria as 90% or
greater (IC90) reduction of growth in comparison with the control.
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Table 1. Structures of discussed ring-substituted hydroxynaphthalenecarboxamides 1–14c; calculated
values of log P, molar volume (MV (cm3)) of R substituents and electronic σ parameters of R
substituents; in vitro antimycobacterial activity (MIC) of compounds in comparison with isoniazid
(INH) and rifampicin (RIF) standards; in vitro antiproliferative assay (IC50) of chosen compounds.
Molecules 2016, 21, 1068 3 of 17 
compound 3c (R = 4-OC2H5) that has higher log P value than compound 10c. Within individual series, 
the lipophilicity increases as follows: OCH3 < OC2H5 < OCH(CH3)2 < OC3H7 < OCH(CH3)CH2CH3 < OC4H9. 
The ortho-substituted derivatives showed the highest calculated log P values, while para-substituted 
derivatives demonstrated the lowest log P values, except 11c (R = 4-OC3H7) and 12c (R = 4-OC4H9) that 
have the same calculated lipophilicity values as the ortho-substituted derivatives. In addition to 
lipophilicity, molar volume (MV) of substituents and electronic σ parameters of substituents are largely 
employed in structure-activity relationship analysis. The corresponding MV and σ values of phenyl 
ring substituents 1–14c are shown in Table 1 and were also predicted by ACD/Percepta. 
 
Scheme 1. Synthesis of N-(alkoxyphenyl)-2-hydroxynaphthalene-1-carboxamides 1–7c and  
N-(alkoxyphenyl)-1-hydroxynaphthalene-2-carboxamides 8–14c. Reagents and conditions: (a) PCl3, 
chlorobenzene, microwave irradiation (MW). 
Table 1. Structures of discussed ring-substituted hydroxynaphthalenecarboxamides 1–14c; calculated 
values of log P, molar volume (MV (cm3)) of R substituents and electronic σ parameters of R substituents; 
in vitro antimycobacterial activity (MIC) of compounds in comparison with isoniazid (INH) and 
rifampicin (RIF) standards; in vitro antiproliferative assay (IC50) of chosen compounds. 
Compound R log P a MV a σ a MIC (µM) IC50 (µM) 
MT MS MK 
1 H 4.49 0 0 94 486 15 >30 
2a 2-OCH3 4.54 37.15 −0.28 852 873 873 - 
2b 3-OCH3 4.51 37.15 0.11 852 218 109 - 
2c 4-OCH3 4.30 37.15 −0.27 852 436 218 - 
3a 2-OC2H5 4.88 53.66 −0.29 26 832 832 >30 
3b 3-OC2H5 4.83 53.66 0.10 813 416 208 - 
3c 4-OC2H5 4.76 53.66 −0.29 26 832 104 >30 
4a 2-OC3H7 5.22 70.16 −0.29 37 796 99 >30 
4b 3-OC3H7 5.14 70.16 0.14 46 398 199 8.97 ± 0.34 
4c 4-OC3H7 5.21 70.16 −0.28 12 398 99 >30 
5a 2-OC4H9 5.53 86.67 −0.28 745 763 763 >30 
5b 3-OC4H9 5.49 86.67 0.14 23 381 190 >30 
5c 4-OC4H9 5.54 86.67 −0.28 745 763 95 >30 
6a 2-OCH(CH3)2 5.15 70.54 −0.47 31 796 99 >30 
6b 3-OCH(CH3)2 5.06 70.54 0.10 778 398 199 8.84 ± 0.22 
6c 4-OCH(CH3)2 5.04 70.54 −0.45 25 796 99 >30 
7a 2-OCH(CH3)CH2CH3 5.47 87.05 −0.27 44 763 95 8.35 ± 1.25 
7b 3-OCH(CH3)CH2CH3 5.40 87.05 0.14 23 12 47 >30 
7c 4-OCH(CH3)CH2CH3 5.40 87.05 −0.27 23 12 95 >30 
Compound R log P a MV a σ a
MIC (µM)
IC50 (µM)
MT MS MK
1 H 4.49 0 0 94 486 15 >30
2a 2-OCH3 4.54 37.15 −0.28 852 873 873 -
2b 3-OCH3 4.51 37.15 0.11 852 218 109 -
2c 4-OCH3 4.30 37.15 −0.27 852 436 218 -
3a 2-OC2H5 4.88 53.66 −0.29 26 832 832 >30
3b 3-OC2H5 4.83 53.66 0.10 813 416 208 -
3c 4-OC2H5 4.76 53.66 −0.29 26 832 104 >30
4a 2-OC3H7 5.22 70.16 −0.29 37 796 99 >30
4b 3-OC3H7 5.14 70.16 0.14 46 398 199 8.97 ± 0.34
4c 4-OC3H7 5.21 70.16 −0.28 12 398 99 >30
5a 2-OC4H9 5.53 86.67 −0.28 745 763 763 >30
5b 3-OC4H9 5.49 86.67 0.14 23 381 190 >30
5c 4-OC4H9 5.54 86.67 −0.28 745 763 95 >30
6a 2-OCH(CH3)2 5.15 70.54 −0.47 31 796 99 >30
6b 3-OCH(CH3)2 5.06 70.54 0.10 778 398 199 8.84 ± 0.22
6c 4-OCH(CH )2 5.04 70.54 −0.45 25 796 99 >30
7a 2-OCH(CH3)CH2CH3 5.47 87.05 −0.27 44 763 95 8.35 ± 1.25
7b 3-OCH(CH3)CH2CH3 5.40 87.05 0.14 23 12 47 >30
7c 4-OCH(CH3)CH2CH3 5.40 87.05 −0.27 23 12 95 >30
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Table 1. Cont. 
Compound R log P a MV a σ a MIC (µM) IC50 (µM) 
MT MS MK 
8 H 4.52 0 0 97 243 15 >30 
9a 2-OCH3 4.61 37.15 −0.28 852 873 873 - 
9b 3-OCH3 4.56 37.15 0.11 852 873 873 - 
9c 4-OCH3 4.37 37.15 −0.27 852 873 873 - 
10a 2-OC2H5 4.92 53.66 −0.29 813 832 832 - 
10b 3-OC2H5 4.88 53.66 0.10 813 832 52 3.02 ± 0.96 
10c 4-OC2H5 4.67 53.66 −0.29 813 832 832 - 
11a 2-OC3H7 5.26 70.16 −0.29 778 796 24 - 
11b 3-OC3H7 5.21 70.16 0.14 24 199 49 1.37 ± 0.72 
11c 4-OC3H7 5.27 70.16 −0.28 778 796 24 >30 
12a 2-OC4H9 5.60 86.67 −0.28 745 763 763 - 
12b 3-OC4H9 5.54 86.67 0.14 23 190 47 1.80 ± 0.32 
12c 4-OC4H9 5.60 86.67 −0.28 745 763 23 >30 
13a 2-OCH(CH3)2 5.18 70.54 −0.47 778 796 796 - 
13b 3-OCH(CH3)2 5.13 70.54 0.10 389 796 796 4.32 ± 0.74 
13c 4-OCH(CH3)2 5.11 70.54 −0.45 778 796 49 9.39 ± 1.39 
14a 2-OCH(CH3)CH2CH3 5.52 87.05 −0.27 745 763 47 9.03 ± 1.18 
14b 3-OCH(CH3)CH2CH3 5.47 87.05 0.14 23 12 47 1.17 ± 0.38 
14c 4-OCH(CH3)CH2CH3 5.46 87.05 −0.27 745 12 23 3.41 ± 0.41 
INH - −0.63 - - 58 117 29 >30 
RIF - 2.24 - - 10 19 0.15 >30 
a calculated using ACD/Percepta ver. 2012 (Advanced Chemistry Development, Inc., Toronto, ON, Canada, 2012); MT = 
M. tuberculosis H37Ra ATCC 25177, MS = Mycobacterium smegmatis ATCC 700084 and MK = M. kansasii DSM 44162. 
2.2. In Vitro Antimycobacterial Evaluation 
The evaluation of the in vitro antimycobacterial activity of the compounds was performed against 
Mycobacterium tuberculosis H37Ra ATCC 25177 (MT), M. kansasii DSM 44162 (MK) and M. smegmatis 
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model pathogens for M. tuberculosis can be used in laboratory studies. Avirulent M. tuberculosis strain 
H37Ra is very closely related to and has similar pathology as human-infecting M. tuberculosis strains, 
making it a good model for study especially because of the lower risk for laboratory workers [19].  
M. kansasii, the most virulent of the NTM, causes nontuberculous mycobacterial lung infections, 
which are now very common, and can be indistinguishable from tuberculosis [20]. M. smegmatis is an 
ideal representative of a fast-growing nonpathogenic microorganism, particularly useful in studying 
basic cellular processes of special relevance to pathogenic mycobacteria [21]. Therefore additionally 
M. kansasii and M. smegmatis were chosen as model species for screening of prospective antimycobacterial 
drugs to control mycobacterial diseases. The potency of the compounds was expressed as the minimum 
inhibitory concentration (MIC) that is defined for mycobacteria as 90% or greater (IC90) reduction of 
growth in comparison with the control. 
Compounds series I and II can be considered as positional isomers that differ from each other by 
the electron density of carboxamide and phenolic moieties as well as by the steric properties of the entire 
scaffolds. Nevertheless, in general, compounds 1–7c demonstrated higher potency against M. tuberculosis, 
while compounds 8–14c showed higher effect against the two NTM strains. Unfortunately, compounds 
of series II showed higher antiproliferative effect on human cells, see Table 1 and Section 2.3. 
The dependences of the antitubercular activity of the compounds against M. tuberculosis expressed 
as log (1/MIC (M)) on lipophilicity expressed as log P are illustrated in Figure 1A,B. Similar trends can 
be observed also for dependences of activities on molar volume (MV) of R substituents; therefore they 
are not illustrated. Based on Figure 1A, it can be stated that compounds of series I in the range of log 
Compound R log P a MV a σ a
MIC (µM)
IC50 (µM)
MT MS MK
8 H 4.52 0 0 97 243 15 >30
9a 2-OCH3 4.61 37.15 −0.28 852 873 873 -
9b 3-OCH3 4.56 37.15 0.11 852 873 873 -
9c 4-OCH3 4.37 37.15 −0.27 852 873 873 -
10a 2-OC2H5 4.92 53.66 −0.29 813 832 832 -
10b 3-OC2H5 4.88 53.66 0.10 813 832 52 3.02 ± 0.96
10c 4-OC2H5 4.67 53.66 −0.29 813 832 832 -
11a 2-OC3H7 5.26 70.16 −0.29 778 796 24 -
11b 3-OC3H7 5.21 70.16 0.14 24 199 49 1.37 ± 0.72
11c 4-OC3H7 5.27 70.16 −0.28 778 796 24 >30
12a 2-OC4H9 5.60 86.67 −0.28 745 763 763 -
12b 3-OC4H9 5.54 86.67 0.14 23 190 47 1.80 ± 0.32
12c 4-OC4H9 5.60 86.67 −0.28 745 763 23 >30
13a 2-OCH(CH3)2 5.18 70.54 −0.47 778 796 796 -
13b 3-OCH(CH3)2 5.13 70.54 0.10 389 796 796 4.32 ± 0.74
13c 4-OCH(CH3)2 5.11 70.54 −0.45 778 796 49 9.39 ± 1.39
14a 2-OCH(CH3)CH2CH3 5.52 87.05 −0.27 745 763 47 9.03 ± 1.18
14b 3-OCH(CH3)CH2CH3 5.47 87.05 0.14 23 12 47 1.17 ± 0.38
14c 4-OCH(CH3)CH2CH3 5.46 87.05 −0.27 745 12 23 3.41 ± 0.41
INH - −0.63 - - 58 117 29 >30
RIF - 2.24 - - 10 19 0.15 >30
a calculated using ACD/Percepta ver. 2012 (Advanced Chemistry Development, Inc., Toronto, ON, Canada,
2012); MT = M. tuberculosis H37Ra ATCC 25177, MS = Mycobacterium smegmatis ATCC 700084 and MK =
M. kansasii DSM 44162.
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Compounds series I and II can be considered as positional isomers that differ from each other
by the electron density of carboxamide and phenolic moieties as well as by the steric properties
of the entire scaffolds. Nevertheless, in general, compounds 1–7c demonstrated higher potency
against M. tuberculosis, while compounds 8–14c showed higher effect against the two NTM strains.
Unfortunately, compounds of series II showed higher antiproliferative effect on human cells, see
Table 1 and Section 2.3.
The dependences of the antitubercular activity of the compounds against M. tuberculosis expressed
as log (1/MIC (M)) on lipophilicity expressed as log P are illustrated in Figure 1A,B. Similar trends can
be observed also for dependences of activities on molar volume (MV) of R substituents; therefore they
are not illustrated. Based on Figure 1A, it can be stated that compounds of series I in the range of log P
values from ca. 4.8 to 5.5 showed potency against M. tuberculosis. The quasi-parabolic dependences
of activity on log P (with log P optimum ca. 5) for the ortho- and para-substituted derivatives can
be observed. The unexpected significant activity slump of both butoxy derivatives 5a and 5c can be
caused by a steric hindrance or limited solubility. On the other hand, for meta-substituted derivatives
of series I, the activity increased up to log P ca. 5.1 (4b, R = 3-OC3H7), see Figure 1B, and then only
insignificantly increased up to 5.49 (compound 5b) with increasing log P. It can be only speculated
whether the activity would remain constant or it would decrease with a further prolongation of the
alkoxy chain. Only 3-propoxy (11b), 3-butoxy (12b) and 3-sec-butoxy (14b) substituted compounds of
series II showed activity comparable with that of series I. In general, the meta-substituted derivatives
of series II demonstrated the same course of dependence (activity increase from log P ca. 5.2) as
the meta-substituted derivatives of series I, see Figure 1B. The ortho- and para-substituted derivatives
of series II expressed no effect; therefore they are not illustrated. It is important to note that the
dependence of the antitubercular activity of the ortho- and para-substituted derivatives on electronic σ
parameters was not observed; the antitubercular activity of the meta-substituted derivatives of series I
and II is influenced by electron-donor properties of the substituents: σ = 0.14 (compounds 4b, 5b, 7b)
vs. σ ≈ 0.10 of the rest of ineffective C(3)′ substituted compounds.
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Figure 1. Relationships between in vitro antitubercular activity against M. tuberculosis log(1/MIC
(mol/L)) and lipophilicity expressed as log P of unsubstituted, ortho- and para-substituted derivatives
of series I (A) and meta-substituted derivatives of series I and II (B).
Additionally, a standard MTT assay was performed on the selected most effective compounds
against M. tuberculosis H37Ra, the MICs of which were previously determined through alamarBlue
assays, see Table 1. The MTT assay is a well-characterized method of assessing cell growth through
measurement of respiration. For the purpose of this assay, a positive result was recorded when the
MTT measured viability of M. tuberculosis H37Ra was less than 70% after exposure to the MIC of
each test compound. As such, a low level of cell viability may suggest inhibition of cell growth
through respiratory inhibition [22]. All the selected compounds, i.e., 3a (R = 2-OC2H5, 30.6%), 3c
(R = 4-OC2H5, 9.96%), 4c (R = 4-OC3H7, 5.90%), 5b (R = 3-OC4H9, 7.38%), 6c (R = 4-OCH(CH3)2,
8.96%), 7b (R = 3-OCH(CH3)CH2CH3, 7.38%), 7c (R = 4-OCH(CH3)CH2CH3, 8.86%), 11b (R = 3-OC3H7,
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15.13%), 12b (R = 3-OC4H9, 9.96%) and 14b (R = 3-OCH(CH3)CH2CH3, 9.96%) showed less than 70%
viability of M. tuberculosis H37Ra at the tested concentration equal to MICs.
Unsubstituted compounds 1 and 8 showed the highest effect against M. kansasii, nevertheless, it
can be stated that in general, the compounds of series II expressed higher potency against M. kansasii
than compounds of series I. The bilinear dependence can be found for compounds of series I,
see Figure 2A, where relationships between the activity against M. kansasii and the lipophilicity
of compounds are illustrated. The activity increases with increasing lipophilicity to the optimum of
log P ca. 5.4, and then a significant activity decrease for butoxy derivatives can be found, similarly as
mentioned above. On the other hand, the effect of the meta- and para-substituted derivatives of series II
increases rapidly up to log P ca. 5, and then the activity is approximately linear, see Figure 2B. Similar
insignificant influences of meta- and para-substituents were observed also by Kos et al. [14,15]. Among
the ortho-substituted derivatives of series II, only 11a (R = 2-OC3H7) and 14a (R = 2-OCH(CH3)CH2CH3)
demonstrated an activity at log P ca. 5.3. The dependences of activities on the molar volume of R
substituents are not illustrated due to their similarity with dependences on lipophilicity.
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The compounds of both series sho ed only moderate activity against M. smegmatis, except
derivatives substituted by a sec-butoxy chain in C(3)′ and C(4)′ positions (compounds 7b, 7c, 14b
and 14c). Becaus especially meta-substituted compounds 7b and 14b showed good ctivity against
. tuberculosis and M. kansa ii, it can be ssumed that the physi ochemical and geometrical rop rties
of the branched sec-butoxy chain are advantageous from the aspect of mycobacteria growth inhibition.
As mentioned above, the discussed compounds are cyclic analogues of salicylanilides. The phenolic
moiety spatially close to the amide group forms a hypothetic six-membered ring by H-bonds with amide
nitrogen, and thus a stable hydrophobic coplanar anionic form with a delocalized negative charge is
generated, which seems to be decisive in the proton motive force. This enables the molecule to penetrate
biological membranes not only as protonated neutral compound but also in the charged state. Thus
salicylanilides are able to induce the uncoupling of oxidative phosphorylation and photophosphorylation
in mitochondria, chloroplasts and other energy-transducing membranes [4,23–26]; therefore also
the discussed structures could be considered as compounds that affect the proton motive force
across membranes ( ncouplers) [4,25–28]. The ortho-substituted derivatives of series I showed
potency especial y against M. tuberculosis. The broa er antimycobact al activity of the meta- and
para-substituted derivatives in comparison with the ortho-substituted compounds can be related to the
steric effect of the spatially close ortho-substituents [29]. A moiety in the ortho position results in a
change of the molecule planarity [30], and different electron densities at the carbonyl and consequently
at the phenolic moiety, which can break the formation of coplanar anionic form with a delocalized
negative charge (i.e., uncoupler effect) and influence the potential of binding of the carboxamide
and the phenolic groups to possible targets (sensitive enzymatic systems affecting proliferative
cell functions as mentioned in Introduction) in a mycobacterial cell. In the case of the meta- and
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para-derivatives, the described secondary steric effect did not manifest [18,29,30]. The para-substituted
as well as the meta-substituted derivatives should have practically a linear/planar structure as was, for
example, described for a similar type of molecule, where the structural analysis displayed a planar
structure [31–34]. Thus, it seems that the mode of action of this type of compounds demonstrates
multitarget activity that should not be very different from that of other planar antimycobacterial
agents [4,6,24,30,35–37]. The lipophilicity of meta- and para-substituted derivatives was found as the
factor conducive to the activity of such structures. More lipophilic structures displayed relatively
higher efficiency, and simultaneously planar structures easier permeate through various types
of membranes.
2.3. In Vitro Antiproliferative Assay
The preliminary in vitro screening of the antiproliferative activity of the most effective
antimycobacterial compounds as well as both standards was performed using Water Soluble
Tetrazolium Salts-1 (WST-1) assay kit [38] and the human monocytic leukemia THP-1 cell line by
means of the method described recently [14]. The antiproliferative activity was evaluated as the IC50
value (compound concentration causing 50% inhibition of cell population proliferation), see Table 1.
A compound is considered as cytotoxic when it demonstrates a toxic effect on cells at the concentration
up to 10 µM [39], and the highest tested concentration that was used for the toxicity assay was 3-fold
this value.
As mentioned above, the compounds of series I showed lower antiproliferative effect than the
compounds of series II, see Table 1. The antiproliferative-efficient compounds inhibit mitochondrial
dehydrogenases (the principle of WST-1 assay kit), the activity of which directly correlates with
the number of metabolically active cells in the culture. All the compounds from series I effective
against M. tuberculosis showed IC50 > 30 µM, i.e., the treatment with this concentration did not lead
to significant antiproliferative effect on THP-1 cells, and compounds 3a, 4c, 5b, 7b and 7c inhibited
selectively vital processes in M. tuberculosis. Based on these observations, it can be concluded that
the discussed amides can be considered as non-toxic agents for subsequent design of novel potential
antitubercular agents. Unfortunately, the potency of these compounds against NTM strains is medium
or moderate, except for compound 7b. The antimycobacterial potency of compounds from series II
is connected with their rather nonselective prokaryote and eukaryote antiproliferative effect; IC50
ranged from 1.2 to 9.4 µM (for comparison, e.g., IC50 of camptothecin, assessed in this line formerly,
was 0.16 ± 0.07 µM), except for compounds 8 (R = H), 11c (R = 4-OC3H7) and 12c (R = 4-OC4H9) with
IC50 > 30 µM, see Table 1. These can be considered as compounds with noteworthy effect against
M. kansasii.
3. Experimental Section
3.1. General Information
All reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) or Merck (Darmstadt,
Germany). Reactions were carried out in a StartSYNTH microwave labstation (Milestone, Sorisole,
Italy). Melting points were determined on a Kofler hot plate apparatus HMK (Franz Kustner Nacht
GK, Dresden, Germany) and left uncorrected. Column chromatography was performed on a 200 mL
column (Sigma-Aldrich) using Silica gel 60 (0.040–0.063 mm, Merck). Infrared (IR) spectra were
recorded on a Smart MIRacle™ ATR ZnSe for Nicolet™ Impact 400 FT-IR spectrometer (Thermo Fisher
Scientific, West Palm Beach, FL, USA). All 1H- and 13C-NMR spectra were recorded on an Agilent
VNMRS 600 MHz system (600 MHz for 1H and 150 MHz for 13C, Agilent Technologies, Santa Clara,
CA, USA) equipped with a triple resonance HCN probe at 25 ◦C in DMSO-d6. Chemical shifts are
reported in ppm (δ) using the signal of the solvent (DMSO; δ(1H) = 2.5 ppm, δ(13C) = 49.5 ppm)
for referencing. High-resolution mass spectra were measured using a high-performance liquid
chromatograph Dionex UltiMate® 3000 (Thermo Fisher Scientific) coupled with an LTQ Orbitrap
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XL™ Hybrid Ion Trap-Orbitrap Fourier Transform Mass Spectrometer (Thermo Fisher Scientific) with
injection into HESI II in the positive mode.
3.2. Synthesis
3.2.1. General Procedure for Synthesis of N-(Alkoxyphenyl)-2-hydroxynaphthalene-1-carboxamides
1–7c and N-(Alkoxyphenyl)-1-hydroxynaphthalene-2-carboxamides 8–14c
2-Hydroxynaphthalene-1-carboxylic acid or 1-hydroxynaphthalene-2-carboxylic acid (5.30 mmol)
and appropriate alkoxyaniline (5.30 mmol) were suspended in 30 mL of dry chlorobenzene.
Phosphorous trichloride (2.65 mmol) was added dropwise, and reacting mixture was heated in
the microwave reactor for 15 min at 130 ◦C using infrared flask-surface control of temperature.
Solvent was evaporated in vacuum; residue solid was washed with 2M HCl and crystallized from
aqueous ethanol. If necessary, column chromatography was used for further purification (mobile
phase DCM:MeOH 19:1).
2-Hydroxy-N-phenylnaphthalene-1-carboxamide (1, CAS 16670-63-6), 2-hydroxy-N-(2-methoxyphenyl)naphtha-
lene-1-carboxamide (2a, CAS 337955-96-1), 2-hydroxy-N-(3-methoxyphenyl)naphthalene-1-carboxamide (2b,
CAS 1463483-65-9) and 2-hydroxy-N-(4-methoxyphenyl)naphthalene-1-carboxamide (2c, CAS 856062-47-0)
were synthesized and characterized recently [16].
N-(2-Ethoxyphenyl)-2-hydroxynaphthalene-1-carboxamide (3a, CAS 858031-71-7). Yield 62%; Mp 116 ◦C
(155–157 ◦C) [40]; IR (cm−1): 3318 (ν NH), 1623 (ν C=O), 1539 (δ NH), 1391 (δ COH), 1284 (ν CN), 1118
(ν CArCO); 1H-NMR (DMSO-d6), δ: 10.48 (br. s, 1H, OH), 9.43 (s, 1H, NH), 8.19 (d, J = 9.2 Hz, 1H,
ArHPhe), 8.15 (d, J = 9.2 Hz, 1H, ArHNaph), 7.88 (d, J = 8.4 Hz, 1H, ArHNaph), 7.84 (d, J = 7.0 Hz, 1H,
ArHNaph), 7.48 (td, J = 8.4 Hz, J = 1.1 Hz, 1H, ArHNaph), 7.34 (td, J = 8.1 Hz, J = 1.1 Hz, 1H, ArHNaph),
7.24 (d, J = 9.2 Hz, 1H, ArHNaph), 7.13–6.96 (m, 3H, ArHPhe), 4.10 (q, J = 7.0 Hz, 2H, CH2), 1.36 (t,
J = 7.0 Hz, 3H, CH3); 13C-NMR (DMSO-d6), δ: 165.06, 152.42, 148.91, 131.81, 131.05, 127.94, 127.73,
127.73, 126.85, 124.50, 124.12, 123.03, 121.74, 120.33, 118.25, 116.60, 112.21, 63.99, 14.57; HR-MS: for
C19H17NO3 [M + H]+ calculated 308.12812 m/z, found 308.12827 m/z.
N-(3-Ethoxyphenyl)-2-hydroxynaphthalene-1-carboxamide (3b). Yield 64%; Mp 133 ◦C; IR (cm−1): 3323 (ν
NH), 1623 (ν C=O), 1536 (δ NH), 1387 (δ COH), 1284 (ν CN), 1158 (ν CArCO); 1H-NMR (DMSO-d6),
δ: 10.34 (s, 1H, NH), 10.05 (br. s, 1H, OH), 7.85 (d, J = 8.8 Hz, 2H, ArHNaph), 7.68 (d, J = 8.1 Hz, 1H,
ArHNaph), 7.53 (t, J = 2.0 Hz, 1H, ArHPhe), 7.46 (td, J = 7.6 Hz, J = 1.3 Hz, 1H, ArHNaph), 7.36–7.19 (m,
4H, ArHNaph, ArHPhe), 6.66 (ddd, J = 7.9 Hz, J = 2.2 Hz, J = 0.7 Hz, 1H, ArHPhe), 4.02 (q, J = 7.0 Hz,
2H, CH2), 1.34 (t, J = 7.0 Hz, 3H, CH3); 13C-NMR (DMSO-d6), δ: 165.68, 158.73, 151.55, 140.74, 131.36,
130.04, 129.34, 127.87, 127.35, 126.85, 123.35, 122.91, 118.58, 118.31, 111.53, 109.19, 105.66, 62.87, 14.60;
HR-MS: for C19H17NO3 [M + H]+ calculated 308.12812 m/z, found 308.12869 m/z.
2-Hydroxy-N-(2-propoxyphenyl)naphthalene-1-carboxamide (4a). Yield 80%; Mp 125 ◦C; IR (cm−1): 3307 (ν
NH), 1622 (ν C=O), 1537 (δ NH), 1390 (δ COH), 1286 (ν CN), 1117 (ν CArCO); 1H-NMR (DMSO-d6), δ:
10.49 (s, 1H, OH), 9.40 (s, 1H, NH), 8.20 (d, J = 9.2 Hz, 1H, ArHPhe), 8.15 (d, J = 9.2 Hz, 1H, ArHNaph),
7.88 (d, J = 8.8 Hz, 1H, ArHNaph), 7.84 (d, J = 7.0 Hz, 1H, ArHNaph), 7.48 (td, J = 7.3 Hz, J = 1.3 Hz, 1H,
ArHNaph), 7.34 (td, J = 7.9 Hz, J = 1.1Hz, 1H, ArHNaph), 7.28 (d, J = 9.2 Hz, 1H, ArHNaph), 7.16–6.95
(m, 3H, ArHPhe), 4.00 (t, J = 6.4 Hz, 2H, CH2), 1.76 (sx, J = 6.8 Hz, 2H, CH2), 0.97 (t, J = 7.3 Hz, 3H,
CH3); 13C-NMR (DMSO-d6), δ: 165.04, 152.45, 149.03, 131.81, 131.10, 127.96, 127.75, 127.63, 126.85,
124.52, 124.11, 123.04, 121.71, 120.27, 118.23, 116.53, 112.09, 69.76, 21.98, 10.35; HR-MS: for C20H19NO3
[M + H]+ calculated 322.14377 m/z, found 322.14438 m/z.
2-Hydroxy-N-(3-propoxyphenyl)naphthalene-1-carboxamide (4b). Yield 87%; Mp 125 ◦C; IR (cm−1): 3352 (ν
NH), 1629 (ν C=O), 1538 (δ NH), 1321 (δ COH), 1276 (ν CN), 1182 (ν CArCO); 1H-NMR (DMSO-d6),
δ: 10.34 (s, 1H, NH), 10.10 (br. s, 1H, OH), 7.85 (d, J = 8.8 Hz, 2H, ArHNaph), 7.68 (d, J = 8.4 Hz, 1H,
ArHNaph), 7.55 (t, J = 1.3 Hz, 1H, ArHPhe), 7.46 (td, J = 7.1 Hz, J = 1.1 Hz, 1H, ArHNaph), 7.38–7.18 (m,
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4H, ArHNaph, ArHPhe), 6.67 (dd, J = 8.1 Hz, J = 2.2 Hz, 1H, ArHPhe), 3.92 (t, J = 6.6 Hz, 2H, CH2), 1.74
(sx, J = 7.0 Hz, 2H, CH2), 0.99 (t, J = 7.3 Hz, 3H, CH3); 13C-NMR (DMSO-d6), δ: 165.69, 158.91, 151.55,
140.74, 131.36, 130.04, 129.33, 127.87, 127.35, 126.87, 123.35, 122.91, 118.58, 118.31, 111.50, 109.22, 105.70,
68.83, 21.98, 10.32; HR-MS: for C20H19NO3 [M + H]+ calculated 322.14377 m/z, found 322.14420 m/z.
2-Hydroxy-N-(4-propoxyphenyl)naphthalene-1-carboxamide (4c). Yield 71%; Mp 153 ◦C; IR (cm−1): 3328 (ν
NH), 1627 (ν C=O), 1531 (δ NH), 1435 (δ COH), 1236 (ν CN), 1169 (ν CArCO); 1H-NMR (DMSO-d6),
δ: 10.23 (s, 1H, NH), 10.00 (br. s, 1H, OH), 7.84 (d, J = 8.4 Hz, 2H, ArHNaph), 7.71 (d, J = 8.8 Hz, 2H,
ArHPhe), 7.68 (d, J = 7.0 Hz, 1H, ArHNaph), 7.45 (td, J = 7.0 Hz, J = 1.1 Hz, 1H, ArHNaph), 7.32 (td,
J = 8.0 Hz, J = 2.0 Hz, 1H, ArHNaph), 7.24 (d, J = 9.2 Hz, 1H, ArHNaph), 6.92 (d, J = 8.8 Hz, 2H, ArHPhe),
3.91 (t, J = 6.6 Hz, 2H, CH2), 1.73 (sx, J = 7.0 Hz, 2H, CH2), 0.99 (t, J = 7.3 Hz, 3H, CH3); 13C-NMR
(DMSO-d6), δ: 165.07; 154.62, 151.51, 132.75, 131.45, 129.89, 127.84, 127.37, 126.76, 123.45, 122.85, 120.71,
118.69, 118.32, 114.38, 69.09, 22.02, 10.32; HR-MS: for C20H19NO3 [M + H]+ calculated 322.14377 m/z,
found 322.14429 m/z.
N-(2-Butoxyphenyl)-2-hydroxynaphthalene-1-carboxamide (5a). Yield 70%; Mp 108 ◦C; IR (cm−1): 3301 (ν
NH), 1621 (ν C=O), 1536 (δ NH), 1392 (δ COH), 1287 (ν CN), 1115 (ν CArCO); 1H-NMR (DMSO-d6), δ:
10.45 (s, 1H, OH), 9.37 (s, 1H, NH), 8.17 (d, J = 8.4 Hz, 1H, ArHPhe), 8.12 (d, J = 9.5 Hz, 1H, ArHNaph),
7.88 (d, J = 8.8 Hz, 1H, ArHNaph), 7.84 (d, J = 7.0 Hz, 1H, ArHNaph), 7.47 (td, J = 7.0 Hz, J = 1.1 Hz, 1H,
ArHNaph), 7.34 (td, J = 7.9 Hz, J = 2.0 Hz, 1H, ArHNaph), 7.27 (d, J = 9.2 Hz, 1H, ArHNaph), 7.13–6.95 (m,
3H, ArHPhe), 4.04 (t, J = 6.4 Hz, 2H, CH2), 1.73 (qi, J = 6.9 Hz, 2H, CH2), 1.42 (sx, J = 7.4 Hz, 2H, CH2),
0.88 (t, J = 7.3 Hz, 3H, CH3); 13C-NMR (DMSO-d6), δ: 165.04, 152.42, 149.08, 131.75, 131.05, 127.94,
127.72, 127.61, 126.82, 124.55, 124.06, 123.03, 121.77, 120.27, 118.22, 116.62, 112.10, 67.95, 30.64, 18.58,
13.57; HR-MS: for C21H21NO3 [M + H]+ calculated 336.15942 m/z, found 336.15982 m/z.
N-(3-Butoxyphenyl)-2-hydroxynaphthalene-1-carboxamide (5b). Yield 46%; Mp 118 ◦C; IR (cm−1): 3350 (ν
NH), 1628 (ν C=O), 1537 (δ NH), 1321 (δ COH), 1276 (ν CN), 1182 (ν CArCO); 1H-NMR (DMSO-d6),
δ: 10.33 (s, 1H, NH), 10.10 (br. s, 1H, OH), 7.85 (d, J = 8.8 Hz, 2H, ArHNaph), 7.67 (d, J = 8.1 Hz, 1H,
ArHNaph), 7.54 (t, J = 1.8 Hz, 1H, ArHPhe), 7.46 (td, J = 7.2 Hz, J = 1.1 Hz, 1H, ArHNaph), 7.36–7.18 (m,
4H, ArHNaph, ArHPhe), 6.69–6,65 (m, 1H, ArHPhe), 3.96 (t, J = 6.4 Hz, 2H, CH2), 1.72 (qi, J = 7.3 Hz,
2H, CH2), 1.45 (sx, J = 7.5 Hz, 2H, CH2), 0.94 (t, J = 7.3 Hz, 3H, CH3); 13C-NMR (DMSO-d6), δ: 165.68,
158.91, 151.55, 140.72, 131.36, 130.02, 129.33, 127.87, 127.34, 126.85, 123.35, 122.89, 118.57, 118.31, 111.51,
109.21, 105.67, 67.01, 30.68, 18.67, 13.60; HR-MS: for C21H21NO3 [M + H]+ calculated 336.15942 m/z,
found 336.15963 m/z.
N-(4-Butoxyphenyl)-2-hydroxynaphthalene-1-carboxamide (5c). Yield 43%; Mp 158 ◦C; IR (cm−1): 3325 (ν
NH), 1619 (ν C=O), 1532 (δ NH), 1435 (δ COH), 1238 (ν CN), 1170 (ν CArCO); 1H-NMR (DMSO-d6),
δ: 10.22 (s, 1H, NH), 10.07 (br. s, 1H, OH), 7.84 (d, J = 8.8 Hz, 2H, ArHNaph), 7.71 (d, J = 9.2 Hz,
2H, ArHPhe), 7.68 (d, J = 7.3 Hz, 1H, ArHNaph), 7.46 (td, J = 7.3 Hz, J = 1.1 Hz, 1H, ArHNaph), 7.32
(td, J = 8.1 Hz, J = 1.1 Hz, 1H, ArHNaph), 7.24 (d, J = 9.2 Hz, 1H, ArHNaph), 6.92 (d, J = 9.2 Hz, 2H,
ArHPhe), 3.95 (t, J = 6.4 Hz, 2H, CH2), 1.70 (qi, J = 6.2 Hz, 2H, CH2), 1.44 (sx, J = 6.6 Hz, 2H, CH2),
0.94 (t, J = 7.1 Hz, 3H, CH3); 13C-NMR (DMSO-d6), δ: 165.07, 154.63, 151.51, 132.74, 131.45, 129.89,
127.84, 127.37, 126.76, 123.45, 122.85, 120.71, 118.69, 118.32, 114.38, 67.27, 30.75, 18.67, 13.62; HR-MS: for
C21H21NO3 [M + H]+ calculated 336.15942 m/z, found 336.15990 m/z.
2-Hydroxy-N-[2-(prop-2-yloxy)phenyl]naphthalene-1-carboxamide (6a). Yield 72%; Mp 141 ◦C; IR (cm−1):
3397 (ν NH), 1624 (ν C=O), 1533 (δ NH), 1396 (δ COH), 1285 (ν CN), 1115 (ν CArCO); 1H-NMR
(DMSO-d6), δ: 10.57 (s, 1H, OH), 9.42 (s, 1H, NH), 8.25 (d, J = 8.1 Hz, 1H, ArHPhe), 8.20 (d, J = 8.8 Hz,
1H, ArHNaph), 7.89 (d, J = 8.8 Hz, 1H, ArHNaph), 7.85 (d, J = 8.1 Hz, 1H, ArHNaph), 7.48 (td, J = 7.5 Hz,
J = 1.5 Hz, 1H, ArHNaph), 7.36 (td, J = 7.0 Hz, J = 0.7 Hz, 1H, ArHNaph), 7.28 (d, J = 8.8 Hz, 1H, ArHNaph),
7.11 (d, J = 4.0 Hz, 2H, ArHPhe), 6.99 (td, J = 7.9 Hz, J = 3.7 Hz, 1H, ArHPhe), 4.68 (sep, J = 6.0 Hz, 1H,
CH), 1.29 (d, J = 6.2 Hz, 6H, CH3); 13C-NMR (DMSO-d6), δ: 164.89, 152.57, 142.50, 131.84, 131.24, 128.64,
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127.96, 127.79, 126.87, 124.26, 124.24, 123.04, 121.54, 120.36, 118.22, 116.23, 113.79, 70.67, 21.75; HR-MS:
for C20H19NO3 [M + H]+ calculated 322.14377 m/z, found 322.14432 m/z.
2-Hydroxy-N-[3-(prop-2-yloxy)phenyl]naphthalene-1-carboxamide (6b). Yield 44%; Mp 102 ◦C; IR (cm−1):
3352 (ν NH), 1628 (ν C=O), 1527 (δ NH), 1319 (δ COH), 1276 (ν CN), 1184 (ν CArCO); 1H-NMR
(DMSO-d6), δ: 10.33 (s, 1H, NH), 10.11 (br. s, 1H, OH), 7.85 (d, J = 9.2 Hz, 2H, ArHNaph), 7.67 (d,
J = 8.0 Hz, 1H, ArHNaph), 7.49 (s, 1H, ArHPhe), 7.46 (td, J = 6.8 Hz, J = 1.7 Hz, 1H, ArHNaph), 7.36–7.17
(m, 4H, ArHNaph, ArHPhe), 6.65 (ddd, J = 8.1 Hz, J = 2.6 Hz, J = 1.6 Hz, 1H, ArHPhe), 4.57 (sep, J = 6.1 Hz,
1H, CH), 1.28 (d, J = 6.2 Hz, 6H, CH3); 13C-NMR (DMSO-d6), δ: 165.71, 157.70, 151.61, 140.81, 131.39,
130.08, 129.40, 127.91, 127.37, 126.91, 123.39, 122.94, 118.58, 118.36, 111.45, 110.33, 106.85, 69.13, 21.84;
HR-MS: for C20H19NO3 [M + H]+ calculated 322.14377 m/z, found 322.14438 m/z.
2-Hydroxy-N-[4-(prop-2-yloxy)phenyl]naphthalene-1-carboxamide (6c). Yield 75%; Mp 133 ◦C; IR (cm−1):
3265 (ν NH), 1625 (ν C=O), 1534 (δ NH), 1435 (δ COH), 1236 (ν CN), 1179 (ν CArCO); 1H-NMR
(DMSO-d6), δ: 10.22 (s, 1H, NH), 10.08 (br. s, 1H, OH), 7.84 (d, J = 8.8 Hz, 2H, ArHNaph), 7.70 (d,
J = 8.8 Hz, 2H, ArHPhe), 7.69 (d, J = 9.2 Hz, 1H, ArHNaph), 7.46 (td, J = 7.5 Hz, J = 1.1 Hz, 1H, ArHNaph),
7.32 (td, J = 7.3 Hz, J = 2.0 Hz, 1H, ArHNaph), 7.24 (d, J = 9.2 Hz, 1H, ArHNaph), 6.91 (d, J = 9.2 Hz, 2H,
ArHPhe), 4.57 (sep, J = 6.0 Hz, 1H, CH), 1.26 (d, J = 5.9 Hz, 6H, CH3); 13C-NMR (DMSO-d6), δ: 165.06,
153.28, 151.49, 132.72, 131.43, 129.86, 127.81, 127.35, 126.75, 123.44, 122.83, 120.72, 118.69, 118.31, 115.84,
69.38, 21.78; HR-MS: for C20H19NO3 [M + H]+ calculated 322.14377 m/z, found 322.14426 m/z.
N-[2-(But-2-yloxy)phenyl]-2-hydroxynaphthalene-1-carboxamide (7a). Yield 60%; Mp 48 ◦C; IR (cm−1): 3398
(ν NH), 1624 (ν C=O), 1521 (δ NH), 1396 (δ COH), 1285 (ν CN), 1112 (ν CArCO); 1H-NMR (DMSO-d6),
δ: 10.56 (s, 1H, OH), 9.40 (s, 1H, NH), 8.26 (d, J = 8.1 Hz, 1H, ArHPhe), 8.19 (d, J = 8.4 Hz, 1H, ArHNaph),
7.89 (d, J = 9.2 Hz, 1H, ArHNaph), 7.84 (d, J = 8.1 Hz, 1H, ArHNaph), 7.48 (td, J = 7.9 Hz, J = 1.5 Hz,
1H, ArHNaph), 7.34 (td, J = 8.1 Hz, J = 1.1 Hz, 1H, ArHNaph), 7.27 (d, J = 8.8 Hz, 1H, ArHNaph), 7.10
(d, J = 4.0 Hz, 2H, ArHPhe), 6.98 (td, J = 8.2 Hz, J = 4.0 Hz, 1H, ArHPhe), 4.87 (sx, J = 6.0 Hz, 1H, CH),
1.70-1.56 (m, 2H, CH2), 1.24 (d, J = 6.2 Hz, 3H, CH3), 0.91 (t, J = 7.3 Hz, 3H, CH3); 13C-NMR (DMSO-d6),
δ: 164.94, 152.66, 147.72, 131.90, 131.31, 128.55, 128.02, 127.81, 126.91, 124.33, 124.23, 123.10, 121.54,
120.27, 118.28, 116.25, 113.47, 75.35, 28.50, 18.99, 9.47; HR-MS: for C21H21NO3 [M + H]+ calculated
336.15942 m/z, found 336.15982 m/z.
N-[3-(But-2-yloxy)phenyl]-2-hydroxynaphthalene-1-carboxamide (7b). Yield 45%; Mp 85 ◦C; IR (cm−1):
3284 (ν NH), 1627 (ν C=O), 1529 (δ NH), 1434 (δ COH), 1275 (ν CN), 1155 (ν CArCO); 1H-NMR
(DMSO-d6), δ: 10.33 (s, 1H, NH), 10.10 (s, 1H, OH), 7.85 (d, J = 9.2 Hz, 2H, ArHNaph), 7.68 (d, J = 8.4 Hz,
1H, ArHNaph), 7.50 (t, J = 2.2 Hz, 1H, ArHPhe), 7.46 (td, J = 7.7 Hz, J = 1.5 Hz, 1H, ArHNaph), 7.36–7.17
(m, 4H, ArHNaph, ArHPhe), 6.65 (ddd, J = 8.1 Hz, J = 1.1 Hz, J = 0.9 Hz, 1H, ArHPhe), 4.33 (sx, J = 6.0 Hz,
1H, CH), 1.72-1.48 (m, 2H, CH2), 1.25 (d, J = 5.9 Hz, 3H, CH3), 0.94 (t, J = 7.3 Hz, 3H, CH3); 13C-NMR
(DMSO-d6), δ: 165.74, 158.06, 151.63, 140.84, 131.40, 130.10, 129.43, 127.93, 127.37, 126.93, 123.41,
122.97, 118.60, 118.37, 111.41, 110.36, 106.79, 74.14, 28.58, 19.09, 9.56; HR-MS: for C21H21NO3 [M + H]+
calculated 336.15942 m/z, found 336.15972 m/z.
N-[4-(But-2-yloxy)phenyl]-2-hydroxynaphthalene-1-carboxamide (7c). Yield 45%; Mp 139 ◦C; IR (cm−1):
3257 (ν NH), 1621 (ν C=O), 1505 (δ NH), 1401 (δ COH), 1232 (ν CN), 1136 (ν CArCO); 1H-NMR
(DMSO-d6), δ: 10.23 (s, 1H, NH), 10.07 (s, 1H, OH), 7.84 (d, J = 8.8 Hz, 2H, ArHNaph), 7.70 (d, J = 9.2 Hz,
2H, ArHPhe), 7.69 (d, J = 7.0 Hz, 1H, ArHNaph), 7.46 (td, J = 7.0 Hz, J = 1.1 Hz, 1H, ArHNaph), 7.32 (td,
J = 7.5 Hz, J = 2.0 Hz, 1H, ArHNaph), 7.24 (d, J = 8.8 Hz, 1H, ArHNaph), 6.91 (d, J = 8.8 Hz, 2H, ArHPhe),
4.34 (sx, J = 5.9 Hz, 1H, CH), 1.72–1.48 (m, 2H, CH2), 1.22 (d, J = 5.9 Hz, 3H, CH3), 0.93 (t, J = 7.3 Hz,
3H, CH3); 13C-NMR (DMSO-d6), δ: 165.13, 153.68, 151.57, 132.77, 131.49, 129.96, 127.91, 127.40, 126.84,
123.50, 122.92, 120.78, 118.73, 118.37, 115.90, 74.43, 28.53, 19.05, 9.50; HR-MS: for C21H21NO3 [M + H]+
calculated 336.15942 m/z, found 336.15974 m/z.
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1-Hydroxy-N-phenylnaphthalene-2-carboxamide (8, CAS 13545-65-8), 1-hydroxy-N-(2-methoxyphenyl)naphtha-
lene-2-carboxamide (9a, CAS 26675-52-5), 1-hydroxy-N-(3-methoxyphenyl)naphthalene-2-carboxamide (9b,
CAS 110677-79-7) and 1-hydroxy-N-(4-methoxyphenyl)naphthalene-2-carboxamide (9c, CAS 98621-48-8)
were synthesized and characterized recently [11].
N-(2-Ethoxyphenyl)-1-hydroxynaphthalene-2-carboxamide (10a, CAS 26639-37-2). Yield 55%; Mp 139 ◦C
(140–142 ◦C) [41]; IR (cm−1): 3424 (ν NH), 1621 (ν C=O), 1538 (δ NH), 1388 (δ COH), 1288 (ν CN),
1117 (ν CArCO); 1H-NMR (DMSO-d6), δ: 13.75 (s, 1H, OH), 10.27 (s, 1H, NH), 8.32 (d, J = 8.2 Hz, 1H,
ArHNaph), 8.07 (d, J = 8.8 Hz, 1H, ArHNaph), 7.91 (d, J = 8.1 Hz, 1H, ArHNaph), 7.73 (dd, J = 7.8 Hz,
J = 1.2 Hz, 1H, ArHPhe), 7.70–7.62 (m, 1H, ArHNaph), 7.62–7.54 (m, 1H, ArHNaph), 7.47 (d, J = 8.8 Hz,
1H, ArHNaph), 7.27–7.18 (m, 1H, ArHPhe), 7.15–7.08 (m, 1H, ArHPhe), 7.00 (t, J = 7.6 Hz, 1H, ArHPhe),
4.11 (q, J = 6.9 Hz, 2H, CH2), 1.34 (t, J = 6.9 Hz, 3H, CH3); 13C-NMR (DMSO-d6), δ: 168.30, 158.61,
151.43, 135.91, 128.82, 127.50, 126.49, 126.08, 125.82, 125.26, 124.85, 123.41, 123.04, 120.27, 118.32, 112.73,
108.78, 63.96, 14.57; HR-MS: for C19H17NO3 [M + H]+ calculated 308.12812 m/z, found 308.12875 m/z.
N-(3-Ethoxyphenyl)-1-hydroxynaphthalene-2-carboxamide (10b). Yield 86%; Mp 130 ◦C; IR (cm−1): 3436 (ν
NH), 1624 (ν C=O), 1532 (δ NH), 1387 (δ COH), 1293 (ν CN), 1174 (ν CArCO); 1H-NMR (DMSO-d6),
δ: 14.00 (br. s, 1H, OH), 10.41 (s, 1H, NH), 8.31 (d, J = 8.3 Hz, 1H, ArHNaph), 8.12 (d, J = 9.0 Hz, 1H,
ArHNaph), 7.92 (d, J = 7.9 Hz, 1H, ArHNaph), 7.67 (ddd, J = 8.1 Hz, J = 6.9 Hz, J = 1.3 Hz, 1H, ArHNaph),
7.62–7.54 (m, 1H, ArHNaph), 7.47 (d, J = 8.8 Hz, 1H, ArHNaph), 7.41–7.33 (m, 2H, ArHPhe), 7.32–7.26 (m,
1H, ArHPhe), 6.76 (ddd, J = 7.8 Hz, J = 2.4 Hz, J = 1.5 Hz, 1H, ArHPhe), 4.04 (q, J = 7.0 Hz, 2H, CH2),
1.35 (t, J = 7.0 Hz, 3H, CH3); 13C-NMR (DMSO-d6), δ: 169.41, 159.88, 158.62, 138.73, 135.94, 129.36,
129.07, 127.41, 125.85, 124.62, 123.00, 123.00, 117.73, 114.01, 110.77, 108.20, 107.55, 63.02, 14.57; HR-MS:
for C19H17NO3 [M + H]+ calculated 308.12812 m/z, found 308.12851 m/z.
N-(4-Ethoxyphenyl)-1-hydroxynaphthalene-2-carboxamide (10c, CAS 109883-65-0). Yield 56%; Mp 152 ◦C
(154–155 ◦C) [41]; IR (cm−1): 3436 (ν NH), 1621 (ν C=O), 1536 (δ NH), 1389 (δ COH), 1299 (ν CN),
1146 (ν CArCO); 1H-NMR (DMSO-d6), δ: 14.21 (br. s, 1H, OH), 10.39 (s, 1H, NH), 8.30 (d, J = 8.3 Hz,
1H, ArHNaph), 8.11 (d, J = 9.0 Hz, 1H, ArHNaph), 7.91 (d, J = 8.1 Hz, 1H, ArHNaph), 7.71–7.52 (m, 4H,
ArHNaph, ArHPhe), 7.45 (d, J = 9.0 Hz, 1H, ArHNaph), 6.96 (d, J = 9.0 Hz, 2H, ArHPhe), 4.03 (q, J = 6.9 Hz,
2H, CH2), 1.33 (t, J = 7.0 Hz, 3H, CH3); 13C-NMR (DMSO-d6), δ: 170.62, 161.37, 157.15, 137.35, 131.73,
130.43, 128.90, 127.27, 126.15, 125.30, 124.48, 124.40, 119.14, 115.79, 108.90, 64.60, 16.07; HR-MS: for
C19H17NO3 [M + H]+ calculated 308.12812 m/z, found 308.12869 m/z.
1-Hydroxy-N-(2-propoxyphenyl)naphthalene-2-carboxamide (11a). Yield 55%; Mp 108 ◦C; IR (cm−1): 3440
(ν NH), 1625 (ν C=O), 1537 (δ NH), 1390 (δ COH), 1240 (ν CN), 1110 (ν CArCO); 1H-NMR (DMSO-d6),
δ: 13.83 (br. s, 1H, OH), 10.26 (s, 1H, NH), 8.35–8.28 (m, 1H, ArHNaph), 8.06 (d, J = 8.8 Hz, 1H, ArHNaph),
7.91 (d, J = 7.7 Hz, 1H, ArHNaph), 7.74–7.55 (m, 3H, ArHNaph, ArHPhe), 7.47 (d, J = 8.8 Hz, 1H, ArHNaph),
7.28–7.20 (m, 1H, ArHPhe), 7.15–7.09 (m, 1H, ArHPhe), 7.00 (td, J = 7.6 Hz, J = 1.4 Hz, 1H, ArHPhe),
4.00 (t, J = 6.4 Hz, 2H, CH2), 1.74 (sx, J = 7.0 Hz, 2H, CH2), 0.95 (t, J = 7.4 Hz, 3H, CH3); 13C-NMR
(DMSO-d6), δ: 168.49, 158.78, 151.86, 135.90, 128.84, 128.49, 126.68, 125.97, 125.80, 125.56, 124.80, 123.26,
123.03, 120.22, 118.25, 112.70, 108.53, 69.66, 22.01, 10.25; HR-MS: for C20H19NO3 [M + H]+ calculated
322.14377 m/z, found 322.14432 m/z.
1-Hydroxy-N-(3-propoxyphenyl)naphthalene-2-carboxamide (11b). Yield 58%; Mp 95 ◦C; IR (cm−1): 3436 (ν
NH), 1627 (ν C=O), 1533 (δ NH), 1330 (δ COH), 1292 (ν CN), 1173 (ν CArCO); 1H-NMR (DMSO-d6), δ:
14.00 (s, 1H, OH), 10.40 (s, 1H, NH), 8.31 (d, J = 8.2 Hz, 1H, ArHNaph), 8.12 (d, J = 9.0 Hz, 1H, ArHNaph),
7.92 (d, J = 8.1 Hz, 1H, ArHNaph), 7.67 (ddd, J = 8.1 Hz, J = 6.9 Hz, J = 1.3 Hz, 1H, ArHNaph), 7.62–7.54
(m, 1H, ArHNaph), 7.47 (d, J = 8.8 Hz, 1H, ArHNaph), 7.42–7.33 (m, 2H, ArHPhe), 7.33–7.25 (m, 1H,
ArHPhe), 6.80–6.73 (m, 1H, ArHPhe), 3.94 (t, J = 6.5 Hz, 2H, CH2), 1.75 (sx, J = 7.0 Hz, 2H, CH2), 0.99
(t, J = 7.3 Hz, 3H, CH3); 13C-NMR (DMSO-d6), δ: 169.41, 159.88, 158.81, 138.73, 135.94, 129.36, 129.05,
127.41, 125.85, 124.62, 123.00, 123.00, 117.73, 114.00, 110.78, 108.23, 107.55, 68.97, 21.96, 10.31; HR-MS:
for C20H19NO3 [M + H]+ calculated 322.14377 m/z, found 322.14426 m/z.
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1-Hydroxy-N-(4-propoxyphenyl)naphthalene-2-carboxamide (11c). Yield 65%; Mp 127 ◦C; IR (cm−1): 3415
(ν NH), 1622 (ν C=O), 1536 (δ NH), 1389 (δ COH), 1297 (ν CN), 1151 (ν CArCO); 1H-NMR (DMSO-d6),
δ: 14.21 (br. s, 1H, OH), 10.39 (s, 1H, NH), 8.30 (d, J = 8.4 Hz, 1H, ArHNaph), 8.11 (d, J = 9.0 Hz, 1H,
ArHNaph), 7.91 (d, J = 7.9 Hz, 1H, ArHNaph), 7.70–7.54 (m, 4H, ArHNaph, ArHPhe), 7.45 (d, J = 8.8 Hz,
1H, ArHNaph), 7.01–6.93 (m, 2H, ArHPhe), 3.93 (t, J = 6.5 Hz, 2H, CH2), 1.73 (sx, J = 7.1 Hz, 2H, CH2),
0.98 (t, J = 7.4 Hz, 3H, CH3); 13C-NMR (DMSO-d6), δ: 169.09, 159.85, 155.80, 135.83, 130.22, 129.92,
127.37, 125.76, 124.64, 123.77, 122.95, 122.88, 117.61, 114.32, 107.38, 69.06, 21.96, 10.28; HR-MS: for
C20H19NO3 [M + H]+ calculated 322.14377 m/z, found 322.14419 m/z.
N-(2-Butoxyphenyl)-1-hydroxynaphthalene-2-carboxamide (12a). Yield 61%; Mp 112 ◦C; IR (cm−1): 3443 (ν
NH), 1626 (ν C=O), 1538 (δ NH), 1390 (δ COH), 1253 (ν CN), 1111 (ν CArCO); 1H-NMR (DMSO-d6),
δ: 13.82 (s, 1H, OH), 10.23 (s, 1H, NH), 8.31 (d, J = 8.2 Hz, 1H, ArHNaph), 8.05 (d, J = 9.0 Hz, 1H,
ArHNaph), 7.92 (d, J = 7.9 Hz, 1H, ArHNaph), 7.73–7.63 (m, 2H, ArHNaph, ArHPhe), 7.62–7.55 (m, 1H,
ArHNaph), 7.47 (d, J = 8.8 Hz, 1H, ArHNaph), 7.28–7.20 (m, 1H, ArHPhe), 7.15–7.09 (m, 1H, ArHPhe),
7.00 (td, J = 7.6 Hz, J = 1.1 Hz, 1H, ArHPhe), 4.04 (t, J = 6.3 Hz, 2H, CH2), 1.70 (qi, J = 7.3 Hz, 2H, CH2),
1.41 (sx, J = 7.4 Hz, 2H, CH2), 0.86 (t, J = 7.3 Hz, 3H, CH3); 13C-NMR (DMSO-d6), δ: 168.50, 158.79,
151.86, 135.88, 128.81, 127.47, 126.67, 125.99, 125.79, 125.53, 124.82, 123.23, 123.01, 120.21, 118.20, 112.67,
108.52, 67.87, 30.64, 18.53, 13.52; HR-MS: for C21H21NO3 [M + H]+ calculated 336.15942 m/z, found
336.15994 m/z.
N-(3-Butoxyphenyl)-1-hydroxynaphthalene-2-carboxamide (12b). Yield 58%; Mp 107 ◦C; IR (cm−1): 3288 (ν
NH), 1633 (ν C=O), 1527 (δ NH), 1389 (δ COH), 1291 (ν CN), 1170 (ν CArCO); 1H-NMR (DMSO-d6), δ:
14.00 (s, 1H, OH), 10.40 (s, 1H, NH), 8.31 (dt, J = 8.2 Hz, J = 0.6 Hz, 1H, ArHNaph), 8.12 (d, J = 8.8 Hz, 1H,
ArHNaph), 7.92 (d, J = 7.9 Hz, 1H, ArHNaph), 7.71–7.63 (m, 1H, ArHNaph), 7.62–7.54 (m, 1H, ArHNaph),
7.47 (d, J = 8.8 Hz, 1H, ArHNaph), 7.42–7.33 (m, 2H, ArHPhe), 7.32–7.25 (m, 1H, ArHPhe), 6.76 (ddd,
J = 7.9 Hz, J = 2.5 Hz, J = 1.3 Hz, 1H, ArHPhe), 3.98 (t, J = 6.5 Hz, 2H, CH2), 1.72 (qi, J = 7.3 Hz, 2H,
CH2), 1.45 (sx, J = 7.4 Hz, 2H, CH2), 0.94 (t, J = 7.5 Hz, 3H, CH3); 13C-NMR (DMSO-d6), δ: 169.34,
159.88, 158.81, 138.72, 135.94, 129.34, 129.05, 127.41, 125.84, 124.62, 123.00, 123.00, 117.73, 114.00, 110.77,
108.23, 107.54, 67.15, 30.67, 18.67, 13.60; HR-MS: for C21H21NO3 [M+H]+ calculated 336.15942 m/z,
found 336.15990 m/z.
N-(4-Butoxyphenyl)-1-hydroxynaphthalene-2-carboxamide (12c). Yield 57%; Mp 124 ◦C; IR (cm−1): 3328 (ν
NH), 1633 (ν C=O), 1532 (δ NH), 1391 (δ COH), 1296 (ν CN), 1149 (ν CArCO); 1H-NMR (DMSO-d6),
δ: 14.22 (br. s, 1H, OH), 10.39 (s, 1H, NH), 8.30 (d, J = 8.2 Hz, 1H, ArHNaph), 8.11 (d, J = 9.0 Hz, 1H,
ArHNaph), 7.91 (d, J = 7.9 Hz, 1H, ArHNaph), 7.71–7.53 (m, 4H, ArHNaph, ArHPhe), 7.45 (d, J = 8.8 Hz,
1H, ArHNaph), 6.97 (d, J = 9.0 Hz, 2H, ArHPhe), 3.97 (t, J = 6.4 Hz, 2H, CH2), 1.70 (qi, J = 7.3 Hz, 2H,
CH2), 1.44 (sx, J = 7.4 Hz, 2H, CH2), 0.94 (t, J = 7.4 Hz, 3H, CH3); 13C-NMR (DMSO-d6), δ: 169.11, 159.87,
155.82, 135.85, 130.22, 128.93, 127.38, 125.77, 124.65, 123.77, 122.97, 122.98, 117.63, 114.32, 107.40, 67.27,
30.70, 18.65, 13.58; HR-MS: for C21H21NO3 [M + H]+ calculated 336.15942 m/z, found 336.15973 m/z.
1-Hydroxy-N-[2-(prop-2-yloxy)phenyl]naphthalene-2-carboxamide (13a). Yield 49%; Mp 123 ◦C; IR (cm−1):
3425 (ν NH), 1629 (ν C=O), 1538 (δ NH), 1391 (δ COH), 1289 (ν CN), 1115 (ν CArCO); 1H-NMR
(DMSO-d6), δ: 13.59 (s, 1H, OH), 10.27 (s, 1H, NH), 8.33 (d, J = 8.4 Hz, 1H, ArHNaph), 8.06 (d, J = 9.0 Hz,
1H, ArHNaph), 7.92 (d, J = 7.9 Hz, 1H, ArHNaph), 7.81 (dd, J = 7.9 Hz, J = 1.5 Hz, 1H, ArHPhe), 7.67 (td,
J = 7.4 Hz, J = 1.5 Hz, 1H, ArHNaph), 7.63–7.55 (m, 1H, ArHNaph), 7.49 (d, J = 8.8 Hz, 1H, ArHNaph),
7.24–7.11 (m, 1H, ArHPhe), 7.16–7.11 (m, 1H, ArHPhe), 6.99 (td, J = 7.6 Hz, J = 1.6 Hz, 1H, ArHPhe), 4.63
(sep, J = 6.0 Hz, 1H, CH), 1.30 (d, J = 6.0 Hz, 6H, CH3); 13C-NMR (DMSO-d6), δ: 167.94, 158.23, 150.13,
135.90, 128.76, 127.50, 127.20, 126.18, 125.79, 124.94, 124.86, 123.48, 123.04, 120.37, 118.46, 114.46, 109.16,
70.94, 21.82; HR-MS: for C20H19NO3 [M + H]+ calculated 322.14377 m/z, found 322.14430 m/z.
1-Hydroxy-N-[3-(prop-2-yloxy)phenyl]naphthalene-2-carboxamide (13b). Yield 77%; Mp 154 ◦C; IR (cm−1):
3301 (ν NH), 1633 (ν C=O), 1530 (δ NH), 1379 (δ COH), 1298 (ν CN), 1156 (ν CArCO); 1H-NMR
(DMSO-d6), δ: 14.00 (s, 1H, OH), 10.39 (s, 1H, NH), 8.31 (d, J = 7.9 Hz, 1H, ArHNaph), 8.12 (d, J = 9.0 Hz,
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1H, ArHNaph), 7.92 (d, J = 7.9 Hz, 1H, ArHNaph), 7.67 (ddd, J = 8.1 Hz, J = 6.9 Hz, J = 1.5 Hz, 1H,
ArHNaph), 7.62–7.55 (m, 1H, ArHNaph), 7.47 (d, J = 9.0 Hz, 1H, ArHNaph), 7.39–7.25 (m, 3H, ArHPhe),
6.77–6.72 (m, 1H, ArHPhe), 4.60 (sep, J = 6.0 Hz, 1H, CH), 1.30 (d, J = 6.0 Hz, 6H, CH3); 13C-NMR
(DMSO-d6), δ: 169.40, 159.87, 157.58, 138.75, 135.93, 129.36, 129.05, 127.41, 125.85, 124.62, 123.00,
123.00, 117.71, 113.94, 111.97, 109.39, 107.51, 69.30, 21.78; HR-MS: for C20H19NO3 [M + H]+ calculated
322.14377 m/z, found 322.14438 m/z.
1-Hydroxy-N-[4-(prop-2-yloxy)phenyl]naphthalene-2-carboxamide (13c). Yield 66%; Mp 173 ◦C; IR (cm−1):
3360 (ν NH), 1623 (ν C=O), 1528 (δ NH), 1379 (δ COH), 1300 (ν CN), 1157 (ν CArCO); 1H-NMR
(DMSO-d6), δ: 14.22 (s, 1H, OH), 10.38 (s, 1H, NH), 8.30 (d, J = 8.1 Hz, 1H, ArHNaph), 8.11 (d, J = 8.8 Hz,
1H, ArHNaph), 7.91 (d, J = 8.1 Hz, 1H, ArHNaph), 7.71–7.53 (m, 4H, ArHNaph, ArHPhe), 7.45 (d, J = 8.8 Hz,
1H, ArHNaph), 6.95 (d, J = 9.0 Hz, 2H, ArHPhe), 4.59 (sep, J = 6.0 Hz, 1H, CH), 1.27 (d, J = 6.0 Hz, 6H,
CH3); 13C-NMR (DMSO-d6), δ: 169.11, 159.85, 154.56, 135.85, 130.16, 128.93, 127.38, 125.79, 124.65,
123.83, 122.97, 122.89, 117.64, 115.61, 107.40, 69.38, 21.76; HR-MS: for C20H19NO3 [M + H]+ calculated
322.14377 m/z, found 322.14422 m/z.
N-[2-(But-2-yloxy)phenyl]-1-hydroxynaphthalene-2-carboxamide (14a). Yield 56%; Mp 60 ◦C; IR (cm−1):
3418 (ν NH), 1627 (ν C=O), 1540 (δ NH), 1389 (δ COH), 1289 (ν CN), 1112 (ν CArCO); 1H-NMR
(DMSO-d6), δ: 13.66 (s, 1H, OH), 10.26 (s, 1H, NH), 8.35–8.29 (m, 1H, ArHNaph), 8.05 (d, J = 9.0 Hz, 1H,
ArHNaph), 7.92 (d, J = 7.5 Hz, 1H, ArHNaph), 7.77 (dd, J = 7.9 Hz, J = 1.5 Hz, 1H, ArHPhe), 7.70–7.63 (m,
1H, ArHNaph), 7.62–7.55 (m, 1H, ArHNaph), 7.48 (d, J = 8.6 Hz, 1H, ArHNaph), 7.25–7.18 (m, 1H, ArHPhe),
7.15–7.09 (m, 1H, ArHPhe), 6.98 (td, J = 7.6 Hz, J = 1.5 Hz, 1H, ArHPhe), 4.43 (sx, J = 6.0 Hz, 1H, CH),
1.76–1.51 (m, 2H, CH2), 1.25 (d, J = 6.0 Hz, 3H, CH3), 0.90 (t, J = 7.4 Hz, 3H, CH3); 13C-NMR (DMSO-d6),
δ: 168.09, 158.40, 150.52, 135.88, 128.76, 127.49, 127.08, 126.32, 125.77, 125.21, 124.85, 123.39, 123.04,
120.25, 118.37, 114.29, 108.98, 75.54, 28.53, 18.85, 9.22; HR-MS: for C21H21NO3 [M + H]+ calculated
336.15942 m/z, found 336.15982 m/z.
N-[3-(But-2-yloxy)phenyl]-1-hydroxynaphthalene-2-carboxamide (14b). Yield 59%; Mp 97 ◦C; IR (cm−1):
3324 (ν NH), 1602 (ν C=O), 1526 (δ NH), 1329 (δ COH), 1296 (ν CN), 1153 (ν CArCO); 1H-NMR
(DMSO-d6), δ: 14.00 (s, 1H, OH), 10.38 (s, 1H, NH), 8.35–8.28 (m, 1H, ArHNaph), 8.12 (d, J = 9.0 Hz, 1H,
ArHNaph), 7.92 (d, J = 7.9 Hz, 1H, ArHNaph), 7.67 (ddd, J = 8.1 Hz, J = 6.8 Hz, J = 1.4 Hz, 1H, ArHNaph),
7.62–7.54 (m, 1H, ArHNaph), 7.47 (d, J = 9.0 Hz, 1H, ArHNaph), 7.40–7.31 (m, 2H, ArHPhe), 7.31–7.24 (m
1H, ArHPhe), 6.75 (ddd, J = 7.8 Hz, J = 2.4 Hz, J = 1.3 Hz, 1H, ArHPhe), 4.38 (sx, J = 6.0 Hz, 1H, CH),
1.77-1.52 (m, 2H, CH2), 1.26 (d, J = 6.0 Hz, 3H, CH3), 0.94 (t, J = 7.4 Hz, 3H, CH3); 13C-NMR (DMSO-d6),
δ: 169.40, 159.88, 157.93, 138.78, 135.93, 129.37, 129.05, 127.41, 125.84, 124.62, 123.00, 123.00, 117.72,
113.94, 111.97, 109.40, 107.55, 74.28, 28.52, 18.99, 9.44; HR-MS: for C21H21NO3 [M + H]+ calculated
336.15942 m/z, found 336.15980 m/z.
N-[4-(But-2-yloxy)phenyl]-1-hydroxynaphthalene-2-carboxamide (14c). Yield 59%; Mp 149 ◦C; IR (cm−1):
3359 (ν NH), 1623 (ν C=O), 1525 (δ NH), 1386 (δ COH), 1302 (ν CN), 1158 (ν CArCO); 1H-NMR
(DMSO-d6), δ: 14.22 (s, 1H, OH), 10.38 (s, 1H, NH), 8.34–8.26 (m, 1H, ArHNaph), 8.11 (d, J = 9.0 Hz, 1H,
ArHNaph), 7.91 (d, J = 7.9 Hz, 1H, ArHNaph), 7.66 (ddd, J = 8.1 Hz, J = 6.9 Hz, J = 1.5 Hz, 1H, ArHNaph),
7.63–7.53 (m, 3H, ArHNaph, ArHPhe), 7.45 (d, J = 8.8 Hz, 1H, ArHNaph), 6.99–6.91 (m, 2H, ArHPhe),
4.37 (sx, J = 6.0 Hz, 1H, CH), 1.75–1.49 (m, 2H, CH2), 1.23 (d, J = 6.0 Hz, 3H, CH3), 0.93 (t, J = 7.4 Hz,
3H, CH3); 13C-NMR (DMSO-d6), δ: 169.11, 159.87, 154.91, 135.85, 130.14, 128.93, 127.38, 125.77, 124.65,
123.85, 122.97, 122.89, 117.63, 115.64, 107.40, 74.37, 28.48, 18.97, 9.41; HR-MS: for C21H21NO3 [M + H]+
calculated 336.15942 m/z, found 336.15990 m/z.
3.3. In Vitro Antimycobacterial Evaluation
Mycobacterium tuberculosis H37Ra ATCC 25177 was grown in Middlebrook broth (MB),
supplemented with Oleic-Albumin-Dextrose-Catalase (OADC) supplement (Becton, Dickinson &
Comp., Franklin Lakes, NJ, USA) and mycobactin J (2 µg/mL). At log phase growth, a culture sample
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(10 mL) was centrifuged at 15,000 rpm/20 min using a bench top centrifuge (Model CR 4-12, Jouan
Inc., Winchester, VA, USA). Following the removal of the supernatant, the pellet was washed in fresh
Middlebrook 7H9GC broth and re-suspended in fresh, ODAC-supplemented MB (10 mL). The turbidity
was adjusted to match McFarland standard No. 1 (3 × 108 cfu) with MB broth. A further 1:20 dilution
of the culture was then performed in MB broth. The antimicrobial susceptibility of M. tuberculosis
was investigated in a 96-well plate format. In these experiments, sterile deionised water (300 µL)
was added to all outer-perimeter wells of the plates to minimize evaporation of the medium in the
test wells during incubation. Each evaluated compound (100 µL) was incubated with M. tuberculosis
(100 µL). Dilutions of each compound were prepared in duplicate. For all synthesized compounds,
final concentrations ranged from 1000 µg/mL to 8 µg/mL. All compounds were dissolved in DMSO,
and subsequent dilutions were made in supplemented MB. The plates were sealed with parafilm and
incubated at 37 ◦C for 7 days. Following incubation, a 10% addition of alamarBlue (AbD Serotec,
Kidlington, UK) was mixed into each well, and readings at 570 nm and 600 nm were taken, initially
for background subtraction and subsequently after 24 h re-incubation. The background subtraction is
necessary for strongly coloured compounds, where the colour may interfere with the interpretation of
any colour change. For non-interfering compounds, a blue colour in the well was interpreted as the
absence of growth, and a pink colour was scored as growth.
The evaluation of the in vitro antimycobacterial activity of the compounds was additionally
performed against Mycobacterium kansasii DSM 44162 and M. smegmatis ATCC 700084. The broth
dilution micro-method in Middlebrook 7H9 medium (Difco, Lawrence, KS, USA) supplemented with
ADC Enrichment (Becton, Dickinson & Comp.) was used to determine the minimum inhibitory
concentration (MIC) as previously described [42]. The compounds were dissolved in DMSO
(Sigma-Aldrich), and the final concentration of DMSO did not exceed 2.5% of the total solution
composition. The final concentrations of the evaluated compounds ranging from 256 µg/mL to
0.125 µg/mL were obtained by twofold serial dilution of the stock solution in microtiter plate with
sterile medium. Bacterial inocula were prepared by transferring colonies from culture to sterile water.
The cell density was adjusted to 0.5 McFarland units using a densitometer (Densi-La-Meter, LIAP,
Riga, Latvia). The final inoculum was made by 1:1000 dilution of the suspension with sterile water.
Drug-free controls, sterility controls and controls consisted of medium and DMSO alone were included.
The determination of results was performed visually after 3 days of static incubation in the darkness at
37 ◦C in an aerobic atmosphere for M. smegmatis and after 7 days of static incubation in the darkness at
37 ◦C in an aerobic atmosphere for M. kansasii.
The minimum inhibitory concentration (MIC) was defined as the lowest concentration of the
compound at which no visible bacterial growth was observed, i.e., the MIC is the lowest concentration
that prevented a visual colour change from blue to pink. MIC is defined for mycobacteria as 90% or
greater (IC90) reduction of growth in comparison with the control. The MIC/IC90 value is routinely
and widely used in bacterial assays and is a standard detection limit according to the Clinical and
Laboratory Standards Institute (CLSI, www.clsi.org). Rifampicin and isoniazid (Sigma-Aldrich) were
used as the standards as they are clinically used antimycobacterial drugs. The results are summarized
in Table 1.
3.4. MTT Assay
For the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, the outer wells
of a 96-well plate were filled with 200 µL of sterile water, and the inner wells were filled with 100 µL
of the tested compound at the MIC to be examined. Compounds were prepared as previously stated
and diluted in Middlebrook media to achieve the desired concentration. Mycobacterium tuberculosis
H37Ra ATCC 25177 was suspended in ODAC supplemented Middlebrook broth at a MacFarland
standard of 1.0 and then diluted 1:20, using Middlebrook broth as a diluent. The diluted mycobacteria
(100 µL) were added to each well containing the compound to be tested. A negative growth control
was composed of 100 µL of DMSO and 100 µL of the media, and the diluted mycobacteria in broth
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absent of inhibiting compounds were used as a positive growth control. All compounds and controls
were prepared in triplicate. Plates were incubated at 37 ◦C for 7 days. After the incubation period, 10%
well volume of MTT reagent was mixed into each well and incubated at 37 ◦C for 24 h. The reagent
and media were then aspirated from the wells, to which 50 µL 99% isopropanol was then added,
and the plates were read at 570 nm. The absorbance readings from the cells, grown in the presence
of the tested compounds, were compared with uninhibited cell growth (using DMSO as the blank)
to determine the relative percent viability. The percent viability was determined through the MTT
assay. The percent viability is calculated through comparison of a measured value against that of
the uninhibited control: %viability = OD570E/OD570P × 100, where OD570E is the reading from the
compound-exposed cells, while OD570P is the reading from the uninhibited cells (positive control).
Cytotoxic potential is determined by a percent viability of <70%.
3.5. In Vitro Antiproliferative Assay
Human monocytic leukemia THP-1 cells were used for in vitro antiproliferative assay. Cells were
obtained from the European Collection of Cell Cultures (ECACC, Salisbury, UK) and routinely cultured
in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2% L-glutamine, 1% penicillin
and streptomycin at 37 ◦C with 5% CO2. Cells were passaged at approximately one-week intervals.
Antiproliferative activity of the compounds was determined using a Water Soluble Tetrazolium
Salts-1 (WST-1, 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium) assay kit
(Roche Diagnostics, Mannheim, Germany) according to the manufacturer’s instructions. The tested
compounds were dissolved in DMSO and added in five increasing concentrations (0.37, 1.1, 3.3, 10
and 30 µM) to the cell suspension in the culture RPMI 1640 medium. The maximum concentration of
DMSO in the assays never exceeded 0.1%. Subsequently, the cells were incubated for 24 h at 37 ◦C with
5% CO2. For WST-1 assays, cells were seeded into 96-well plates (5 × 104 cells/well in 100 µL culture
medium) in triplicate in serum-free RPMI 1640 medium, and measurements were taken 24 h after
the treatment with the compounds. The median inhibition concentration values, IC50, were deduced
through the production of a dose-response curve. All data were evaluated using GraphPad Prism 5.00
software (GraphPad Software, San Diego, CA, USA). The results are summarized in Table 1.
4. Conclusions
Series of nineteen N-(alkoxyphenyl)-2-hydroxynaphthalene-1-carboxamides (1–7c) and their
nineteen positional isomers N-(alkoxyphenyl)-1-hydroxynaphthalene-2-carboxamides (8–14c) were
prepared by means of microwave synthesis and subsequently characterized. All the compounds
were tested for their in vitro antimycobacterial activity against M. tuberculosis, M. smegmatis and
M. kansasii. The most effective compounds were also tested for their in vitro antiproliferative effect
against the THP-1 cells. Lipophilicity was found as the main physicochemical parameter influencing
the activity, and more lipophilic compounds expressed higher potency. In general, N-(alkoxyphenyl)-
2-hydroxynaphthalene-1-carboxamides showed higher activity against M. tuberculosis, while
N-(alkoxyphenyl)-1-hydroxynaphthalene-2-carboxamides demonstrated higher effect against
M. smegmatis and M. kansasii, but also stronger antiproliferative effect against the human THP-1
cell line. 2-Hydroxy-N-(4-propoxyphenyl)naphthalene-1-carboxamide (4c) showed the highest activity
(MIC = 12 µM) against M. tuberculosis with insignificant toxicity, while N-[3-(but-2-yloxy)phenyl]- (7b)
and N-[4-(but-2-yloxy)phenyl]-2-hydroxynaphthalene-1-carboxamide (7c) demonstrated high activity
against all three mycobacterial strains and insignificant toxicity. Their potency is comparable with that
of rifampicin. The performed MTT assay of the selected most efficient compounds showed that they
cause a decrease of mycobacterial cell metabolism. Based on the presented results it can be concluded
that some of the discussed amides can be considered as promising agents for subsequent design of
novel antimycobacterial agents.
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